In a regulated environment, a consulting recommendation is only worth as much as the paper trail behind it — if an engagement can’t show FDA, on re-inspection, exactly how a conclusion was reached, the conclusion doesn’t hold. Methodology is what makes an engagement auditable after the fact and repeatable across different practitioners, different sites, and different findings, rather than depending on whoever happens to be in the room. Every phase below produces a specific, dated, ownable artifact for this reason — not a summary slide.
How an Engagement Runs
1. Diagnostic Gap Assessment
The engagement opens with an honest inventory against the exact regulatory criteria that govern the problem — not a general health check.
- For a readiness engagement, this means a document inventory gap assessment across every zone FDA actually inspects under CPGM 7356.002 (manufacturing, laboratory controls, quality systems, facilities and equipment, materials) — testing, not assuming, whether any given record can be retrieved within 15 minutes of a simulated request.
- For a remediation engagement, this means mapping the finding directly to the specific 21 CFR Part 211 subsection FDA cited, before any corrective language is drafted.
- This phase deliberately does not produce a polished package. It produces a map of what exists, what’s current, what’s overdue, and what can’t be located at all — the same standard the client’s own inspection back room will be held to.
2. Root Cause Depth Analysis
Every finding is traced through four levels before a corrective action is proposed, using the XGene Root Cause Depth Test.
- Level 1 (Symptom): what FDA actually observed. Level 2 (Procedural): which specific procedure failed and how. Level 3 (System): what management-system condition allowed that procedure to drift undetected until the inspection. Level 4 (Root Cause): what has to change across the quality system to prevent recurrence elsewhere.
- Root cause work is co-authored by the manufacturing/quality operations staff who work in the affected system and a regulatory writer — never regulatory affairs alone — using ICH Q9(R1) tools (fishbone, 5-Why, fault tree), and it must reach a minimum of three causal levels. “Human error” is treated as a symptom category, not an accepted root cause.
- Where the finding involves a specific cited condition, a retrospective scope assessment is completed first: how many batches, processes, or systems were affected by the same condition, with a documented disposition decision for each — before the response is drafted, not promised for later.
3. Structured Remediation / Readiness Architecture
The findings from Phase 2 are built into a named, structured framework — not a narrative report.
- Every corrective or preventive commitment carries four required elements: a specific completion date, a named responsible person, a measurable success criterion (a metric, not an activity like “will monitor compliance”), and a defined independent effectiveness-verification plan.
- For readiness engagements, this is where equipment qualification status, the CAPA log (every item open past 90 days gets a documented extended-timeline justification), the annual product review schedule, and batch record correction integrity are each built into a structured evidence package tied to the specific inspection zone they support.
- For remediation engagements, this is where Immediate Corrective Action, Root Cause Analysis, and Systemic Preventive Action are assembled as three simultaneous, cross-referenced layers — not a sequential checklist — so a reviewer can trace any single commitment back to the specific observation and root cause it resolves.
4. Stress-Test Verification
Before anything is finalized, it’s tested against how an actual investigator behaves — not reviewed against an internal checklist.
- A mock inspection or dry-run response review is conducted by a senior practitioner who has personally sat across the table from FDA investigators, replicating real sequencing: opening conference, systems-based document requests, back-room retrieval testing, and a formal closeout with an honest, 483-equivalent observation list.
- Every observation is run through the same verification logic: what specifically was wrong, why did the system allow it, how has the system changed so it can’t happen again, and how will that be proven.
- Front-room and back-room protocol is rehearsed against real response-time standards (same-day for standard records, next-morning for complex packages), because a slow document retrieval mid-inspection changes how an investigator reads everything that follows.
5. Close-Out & Effectiveness Verification
The engagement doesn’t close when the deliverable is submitted — it closes when the effectiveness check defined in Phase 3 has actually run.
- The independent verification plan is executed against its stated metric, timeframe, and owner, and the result is documented — not assumed.
- For remediation programs extending past six months, progress updates are provided proactively, on a defined cadence, rather than only in response to a request.
- The client is handed a package built to survive a subsequent inspection on its own terms, not just to close the finding that prompted the engagement.
How This Scales
The five phases don’t change with project size — only their depth and staffing do. A single Module 3 section gap assessment moves through all five phases in days, run by one senior consultant end to end. A multi-site remediation program runs the same five phases in parallel across sites, staffed with fractional or embedded leadership from consultants whose own operating background matches the specific gap — sterile manufacturing, combination products, data integrity — for the duration of the engagement. What doesn’t compress is the sequence itself: no phase is skipped to save time, because skipping the diagnostic or the stress test is exactly the pattern that produces a CAPA that closes on paper and reopens at the next inspection.